Roche Receives CE Mark for Alzheimer's Blood Test, Aiming to Accelerate Diagnosis
Roche has announced the receipt of a CE Mark for its Elecsys® pTau217 blood test, developed in collaboration with Eli Lilly and Company. This test is designed to detect phosphorylated Tau (pTau) 217 protein, a key indicator of amyloid pathology associated with Alzheimer's disease. The Elecsys® pTau217 test offers a minimally invasive alternative to traditional diagnostic methods like PET-CT scans and cerebrospinal fluid assessments, which are often costly and less accessible. The test aims to provide a faster and more convenient diagnosis for Alzheimer's, potentially reducing the average 3.5-year delay in diagnosing dementia. This development is significant as it could help address the issue of underdiagnosis, with an estimated 75% of dementia cases currently undiagnosed. 
